Raras
Buscar doenças, sintomas, genes...
NÃO RARA NA EUROPA: Degenerescência macular relacionada com a idade
ORPHA:279DOENÇA RARA

Perda de visão que acontece com a idade, na mácula (a parte central da retina), causada pelo desgaste ou deterioração da própria retina.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Perda de visão que acontece com a idade, na mácula (a parte central da retina), causada pelo desgaste ou deterioração da própria retina.

🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

👁️
Olhos
10 sintomas
🧬
Pele e cabelo
2 sintomas
🦴
Ossos e articulações
2 sintomas
💪
Músculos
1 sintomas
🧠
Neurológico
1 sintomas
❤️
Coração
1 sintomas

+ 9 sintomas em outras categorias

Características mais comuns

Degeneração macular
Distrofia macular
Discromatopsia vermelho-verde
Anel perifoveal de hiperautofluorescência
Alta miopia
Acuidade visual reduzida
26sintomas
Sem dados (26)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 26 características clínicas mais associadas, ordenadas por frequência.

Degeneração macularMacular degeneration
Distrofia macularMacular dystrophy
Discromatopsia vermelho-verdeRed-green dyschromatopsia
Anel perifoveal de hiperautofluorescênciaPerifoveal ring of hyperautofluorescence
Alta miopiaHigh myopia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa11
Últimos 10 anos22publicações
Pico20214 papers
Linha do tempo
20202015Hoje · 2026📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

15 genes identificados com associação a esta condição.

FBLN5Fibulin-5Disease-causing germline mutation(s) inRestrito
FUNÇÃO

Essential for elastic fiber formation, is involved in the assembly of continuous elastin (ELN) polymer and promotes the interaction of microfibrils and ELN (PubMed:18185537). Stabilizes and organizes elastic fibers in the skin, lung and vasculature (By similarity). Promotes adhesion of endothelial cells through interaction of integrins and the RGD motif. Vascular ligand for integrin receptors which may play a role in vascular development and remodeling (PubMed:10428823). May act as an adapter th

LOCALIZAÇÃO

SecretedSecreted, extracellular space, extracellular matrix

VIAS BIOLÓGICAS (2)
Molecules associated with elastic fibresElastic fibre formation
MECANISMO DE DOENÇA

Charcot-Marie-Tooth disease, demyelinating, type 1H

An autosomal dominant demyelinating form of Charcot-Marie-Tooth disease, a disorder of the peripheral nervous system, characterized by progressive weakness and atrophy, initially of the peroneal muscles and later of the distal muscles of the arms. Charcot-Marie-Tooth disease is classified in two main groups on the basis of electrophysiologic properties and histopathology: primary peripheral demyelinating neuropathies (designated CMT1 when they are dominantly inherited) and primary peripheral axonal neuropathies (CMT2). Demyelinating neuropathies are characterized by severely reduced nerve conduction velocities (less than 38 m/sec), segmental demyelination and remyelination with onion bulb formations on nerve biopsy, slowly progressive distal muscle atrophy and weakness, absent deep tendon reflexes, and hollow feet. CMT1H is characterized by peripheral sensorimotor neuropathy with onset usually in adulthood. Affected individuals present with foot deformities, upper or lower limb sensory disturbances, and motor deficits, mainly impaired gait. Rare patients may have hyperelastic skin or develop age-related macular degeneration.

EXPRESSÃO TECIDUAL(Ubíquo)
Aorta
795.1 TPM
Fibroblastos
292.3 TPM
Artéria coronária
255.6 TPM
Útero
195.1 TPM
Artéria tibial
192.2 TPM
OUTRAS DOENÇAS (7)
macular degeneration, age-related, 3cutis laxa, autosomal recessive, type 1Acutis laxa, autosomal dominant 2Charcot-Marie-Tooth disease, demyelinating, IIA 1H
HGNC:3602UniProt:Q9UBX5
MFSD8Major facilitator superfamily domain-containing protein 8Disease-causing germline mutation(s) inTolerante
FUNÇÃO

Outward-rectifying chloride channel involved in endolysosomal chloride homeostasis, membrane fusion and function. Conducts chloride currents up to hundreds of picoamperes. Regulates lysosomal calcium content by reducing the lysosomal membrane potential, thereby activating TRPML1 channel and further release of lysosomal calcium ions. Regulates the pH in endolysosomal compartments and may contribute to progressive acidification from endosome to lysosome. Permeable to other halides such as iodide a

LOCALIZAÇÃO

Endosome membraneLysosome membrane

MECANISMO DE DOENÇA

Ceroid lipofuscinosis, neuronal, 7

A form of neuronal ceroid lipofuscinosis with onset in early childhood. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The lipopigment patterns observed most often in neuronal ceroid lipofuscinosis type 7 comprise mixed combinations of granular, curvilinear, fingerprint, and rectilinear profiles.

EXPRESSÃO TECIDUAL(Ubíquo)
Cérebro - Hemisfério cerebelar
20.7 TPM
Ovário
16.8 TPM
Cervix Endocervix
16.7 TPM
Cerebelo
16.7 TPM
Útero
16.4 TPM
OUTRAS DOENÇAS (3)
macular dystrophy with central cone involvementneuronal ceroid lipofuscinosis 7cone-rod dystrophy
HGNC:28486UniProt:Q8NHS3
RAX2Retina and anterior neural fold homeobox protein 2Disease-causing germline mutation(s) inTolerante
FUNÇÃO

May be involved in modulating the expression of photoreceptor specific genes. Binds to the Ret-1 and Bat-1 element within the rhodopsin promoter

LOCALIZAÇÃO

Nucleus

MECANISMO DE DOENÇA

Macular degeneration, age-related, 6

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

EXPRESSÃO TECIDUAL(Baixa expressão)
Pituitária
1.9 TPM
Fallopian Tube
0.9 TPM
Útero
0.7 TPM
Cervix Endocervix
0.1 TPM
Testículo
0.1 TPM
OUTRAS DOENÇAS (4)
retinitis pigmentosa 95cone-rod dystrophy 11age related macular degeneration 6cone-rod dystrophy
HGNC:18286UniProt:Q96IS3
CST3Cystatin-CCandidate gene tested inTolerante
FUNÇÃO

As an inhibitor of cysteine proteinases, this protein is thought to serve an important physiological role as a local regulator of this enzyme activity

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Cerebral amyloid angiopathy, CST3-related

An autosomal dominant disorder characterized by cystatin C amyloid accumulation in the walls of arteries, arterioles, and sometimes capillaries and veins of the brain, and in various organs including lymphoid tissue, spleen, salivary glands, and seminal vesicles. Amyloid deposition in the cerebral vessels results in intracranial hemorrhage and premature stroke. Cystatin C levels in the cerebrospinal fluid are abnormally low.

EXPRESSÃO TECIDUAL(Ubíquo)
Brain Putamen basal ganglia
653.3 TPM
Brain Caudate basal ganglia
619.9 TPM
Cérebro - Amígdala
598.5 TPM
Córtex cerebral
585.7 TPM
Brain Frontal Cortex BA9
531.0 TPM
OUTRAS DOENÇAS (2)
ACys amyloidosisage related macular degeneration 11
HGNC:2475UniProt:P01034
CX3CR1CX3C chemokine receptor 1Candidate gene tested inDesconhecido
FUNÇÃO

Receptor for the C-X3-C chemokine fractalkine (CX3CL1) present on many early leukocyte cells; CX3CR1-CX3CL1 signaling exerts distinct functions in different tissue compartments, such as immune response, inflammation, cell adhesion and chemotaxis (PubMed:12055230, PubMed:23125415, PubMed:9390561, PubMed:9782118). CX3CR1-CX3CL1 signaling mediates cell migratory functions (By similarity). Responsible for the recruitment of natural killer (NK) cells to inflamed tissues (By similarity). Acts as a reg

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (4)
G alpha (i) signalling eventsChemokine receptors bind chemokinesRespiratory syncytial virus (RSV) attachment and entryRSV-host interactions
MECANISMO DE DOENÇA

Macular degeneration, age-related, 12

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

EXPRESSÃO TECIDUAL(Tecido-específico)
Sangue
10.8 TPM
Substância negra
8.1 TPM
Brain Spinal cord cervical c-1
8.0 TPM
Baço
5.4 TPM
Hipotálamo
4.8 TPM
OUTRAS DOENÇAS (3)
age related macular degeneration 12susceptibility to HIV infectioncoronary heart disease, susceptibility to, 1
HGNC:HGNC:2558UniProt:P49238
C2Complement C2Candidate gene tested inTolerante
FUNÇÃO

Precursor of the catalytic component of the C3 and C5 convertase complexes, which are part of the complement pathway, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:12878586, PubMed:17027507, PubMed:18204047, PubMed:39914456, PubMed:39814882). Component C2 is part of the classical, lectin and GZMK complement systems (PubMed:12878586, PubMed:17027507, PubMed:18204047, PubMed:22691502, PubMed:39914456) C

LOCALIZAÇÃO

SecretedCell surface

VIAS BIOLÓGICAS (1)
Initial triggering of complement
MECANISMO DE DOENÇA

Macular degeneration, age-related, 14

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

OUTRAS DOENÇAS (3)
complement component 2 deficiencyimmunodeficiency due to a classical component pathway complement deficiencyage related macular degeneration 14
HGNC:1248UniProt:P06681
CFHComplement factor HCandidate gene tested inAltamente restrito
FUNÇÃO

Glycoprotein that plays an essential role in maintaining a well-balanced immune response by modulating complement activation. Acts as a soluble inhibitor of complement, where its binding to self markers such as glycan structures prevents complement activation and amplification on cell surfaces (PubMed:21285368, PubMed:21317894, PubMed:25402769). Accelerates the decay of the complement alternative pathway (AP) C3 convertase C3bBb, thus preventing local formation of more C3b, the central player of

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Regulation of Complement cascade
MECANISMO DE DOENÇA

Basal laminar drusen

Drusen are extracellular deposits that accumulate below the retinal pigment epithelium on Bruch membrane. Basal laminar drusen refers to an early adult-onset drusen phenotype that shows a pattern of uniform small, slightly raised yellow subretinal nodules randomly scattered in the macula. In later stages, these drusen often become more numerous, with clustered groups of drusen scattered throughout the retina. In time these small basal laminar drusen may expand and ultimately lead to a serous pigment epithelial detachment of the macula that may result in vision loss.

OUTRAS DOENÇAS (10)
complement factor H deficiencybasal laminar drusendense deposit diseaseDoyne honeycomb retinal dystrophy
HGNC:4883UniProt:P08603
ARMS2Age-related maculopathy susceptibility protein 2Candidate gene tested inTolerante
LOCALIZAÇÃO

Cytoplasm

MECANISMO DE DOENÇA

Macular degeneration, age-related, 8

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

OUTRAS DOENÇAS (1)
age related macular degeneration 8
HGNC:HGNC:32685UniProt:P0C7Q2
APOEApolipoprotein ECandidate gene tested inTolerante
FUNÇÃO

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:14754908, PubMed:1911868, PubMed:6860692). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:14754908, PubMed:1911868, PubMed:1917954, PubMed:23620513, PubMed:2762297, PubMed:6860692, PubMed:9395455). Apolipoproteins are amphipathic mole

LOCALIZAÇÃO

SecretedSecreted, extracellular spaceSecreted, extracellular space, extracellular matrixExtracellular vesicleEndosome, multivesicular body

VIAS BIOLÓGICAS (9)
Nuclear signaling by ERBB4Scavenging by Class A ReceptorsTranscriptional regulation by the AP-2 (TFAP2) family of transcription factorsChylomicron assemblyHDL remodeling
MECANISMO DE DOENÇA

Hyperlipoproteinemia 3

A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.

OUTRAS DOENÇAS (6)
lipoprotein glomerulopathyhyperlipoproteinemia type 3sea-blue histiocyte syndromeAlzheimer disease 2
HGNC:613UniProt:P02649
CFBComplement factor BCandidate gene tested inTolerante
FUNÇÃO

Precursor of the catalytic component of the C3 and C5 convertase complexes of the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:3638964, PubMed:624565, PubMed:6554279, PubMed:6919543, PubMed:9748277). The alternative complement pathway acts as an amplification loop that enhances other complement pathways (classical, lectin and GZMK) by promoting formation

LOCALIZAÇÃO

SecretedCell surface

VIAS BIOLÓGICAS (1)
Alternative complement activation
MECANISMO DE DOENÇA

Macular degeneration, age-related, 14

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

OUTRAS DOENÇAS (4)
complement factor b deficiencyatypical hemolytic uremic syndrome with complement gene abnormalityage related macular degeneration 14atypical hemolytic-uremic syndrome with B factor anomaly
HGNC:1037UniProt:P00751
HMCN1Hemicentin-1Candidate gene tested inRestrito
FUNÇÃO

Involved in transforming growth factor beta-mediated rearrangement of the podocyte cytoskeleton which includes reduction of F-actin fibers and broadening, flattening and elongation of podocytes (PubMed:29488390). Plays a role in basement membrane organization (By similarity). May promote cleavage furrow maturation during cytokinesis in preimplantation embryos (By similarity). May play a role in the architecture of adhesive and flexible epithelial cell junctions (By similarity). May play a role d

LOCALIZAÇÃO

Secreted, extracellular space, extracellular matrix, basement membraneCytoplasmCell junctionCleavage furrow

MECANISMO DE DOENÇA

Macular degeneration, age-related, 1

A form of age-related macular degeneration, a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin-containing structure known as Bruch membrane.

EXPRESSÃO TECIDUAL(Tecido-específico)
Aorta
38.2 TPM
Artéria coronária
12.6 TPM
Esôfago - Muscular
12.1 TPM
Pulmão
11.9 TPM
Esôfago - Junção
8.6 TPM
INTERAÇÕES PROTEICAS (2)
OUTRAS DOENÇAS (1)
age related macular degeneration 1
HGNC:HGNC:19194UniProt:Q96RW7
ABCA4Retinal-specific phospholipid-transporting ATPase ABCA4Candidate gene tested inTolerante
FUNÇÃO

Flippase that catalyzes in an ATP-dependent manner the transport of retinal-phosphatidylethanolamine conjugates like 11-cis and all-trans isomers of N-retinylidene-phosphatidylethanolamine (N-Ret-PE) from the lumen to the cytoplasmic leaflet of photoreceptor outer segment disk membranes, where 11-cis-retinylidene-phosphatidylethanolamine is then isomerized to its all-trans isomer and reduced by RDH8 to produce all-trans-retinol. This transport activity ensures that all-trans-retinal generated fr

LOCALIZAÇÃO

MembraneEndoplasmic reticulumCytoplasmic vesicleCell projection, cilium, photoreceptor outer segment

VIAS BIOLÓGICAS (2)
The canonical retinoid cycle in rods (twilight vision)ABC-family proteins mediated transport
MECANISMO DE DOENÇA

Stargardt disease 1

An autosomal recessive form of Stargardt disease, a retinal degenerative disease characterized by macular dystrophy, progressive bilateral atrophy of the foveal retinal pigment epithelium, and accumulation of fluorescent flecks around the macula and/or in the central and near-peripheral areas of the retina. STGD1 patients typically lose central vision in their first or second decade of life.

OUTRAS DOENÇAS (8)
severe early-childhood-onset retinal dystrophyretinitis pigmentosa 19cone-rod dystrophy 3ABCA4-related retinopathy
HGNC:34UniProt:P78363
CFHR1Complement factor H-related protein 1Candidate gene tested inTolerante
FUNÇÃO

Involved in complement regulation. The dimerized forms have avidity for tissue-bound complement fragments and efficiently compete with the physiological complement inhibitor CFH. Can associate with lipoproteins and may play a role in lipid metabolism

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Regulation of Complement cascade
MECANISMO DE DOENÇA

Hemolytic uremic syndrome, atypical, 1

An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.

OUTRAS DOENÇAS (4)
dense deposit diseaseC3 glomerulonephritisage related macular degeneration 1hemolytic uremic syndrome, atypical, susceptibility to, 1
HGNC:4888UniProt:Q03591
CFHR3Complement factor H-related protein 3Candidate gene tested inTolerante
FUNÇÃO

Might be involved in complement regulation

LOCALIZAÇÃO

Secreted

VIAS BIOLÓGICAS (1)
Regulation of Complement cascade
MECANISMO DE DOENÇA

Hemolytic uremic syndrome, atypical, 1

An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease.

OUTRAS DOENÇAS (3)
C3 glomerulonephritishemolytic uremic syndrome, atypical, susceptibility to, 1age related macular degeneration 1
HGNC:16980UniProt:Q02985
C3Complement C3Candidate gene tested inRestrito
FUNÇÃO

Precursor of non-enzymatic components of the classical, alternative, lectin and GZMK complement pathways, which consist in a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system Non-enzymatic component of C5 convertase (PubMed:28264884, PubMed:31507604, PubMed:3653927, PubMed:3897448). Generated following cleavage by C3 convertase, it covalently attaches to the surface of pathogens, where it acts as an opsonin that ma

LOCALIZAÇÃO

SecretedCell surface

VIAS BIOLÓGICAS (2)
Post-translational protein phosphorylationRegulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
MECANISMO DE DOENÇA

Complement component 3 deficiency

A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis.

OUTRAS DOENÇAS (4)
complement component 3 deficiencyatypical hemolytic uremic syndrome with complement gene abnormalityatypical hemolytic-uremic syndrome with C3 anomalyage related macular degeneration 9
HGNC:1318UniProt:P01024

Variantes genéticas (ClinVar)

199 variantes patogênicas registradas no ClinVar.

🧬 C3: NM_000064.4(C3):c.2089G>A (p.Gly697Ser) ()
🧬 C3: NM_000064.4(C3):c.2584-1G>A ()
🧬 C3: NM_000064.4(C3):c.619C>T (p.Arg207Ter) ()
🧬 C3: NM_000064.4(C3):c.3808C>T (p.Gln1270Ter) ()
🧬 C3: NM_000064.4(C3):c.3154+1G>A ()
Ver todas no ClinVar

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — NÃO RARA NA EUROPA: Degenerescência macular relacionada com a idade

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

Pesquisa e ensaios clínicos

Nenhum ensaio clínico registrado para esta condição.

🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

📖Melhor nível de evidência: Revisão
Timeline de publicações
0 papers (10 anos)
#1

Telemedicine-based diabetic retinopathy screening in patients over 70 Years: a French cohort study within the OPHDIAT network.

Diabetes & metabolism2026 Mar

To assess the outcomes of teleophthalmology-based diabetic retinopathy (DR) screening in individuals over 70 years within the OPHDIAT network and to compare them with those of patients aged 18-69 years. A cohort of 16,459 diabetic patients, without known DR or with mild non-proliferative DR (NPDR), screened in 2024 in 32 OPHDIAT centers, was included and divided into two groups: < 70 years (n = 13,639) and ≥ 70 years (n = 2,820). Two non-mydriatic retinal photographs per eye were analyzed by certified ophthalmologists. Among patients aged ≥70 years, 21.3% (95% CI: 19.8-22.8) had any DR, and 6.1% (95% CI: 5.2-6.9) were referred to an ophthalmologist for moderate NPDR or a more severe form of the disease, including suspected macular edema. These proportions did not significantly differ from those found in patients < 70 years: 21.9% (95% CI: 21.2-22.6) and 6.1% (95% CI:5.6-6.5), respectively. Severe NPDR or proliferative DR were rare in both groups (1.0%, 95% CI: 0.6-1.4% vs. 1.7%, 95% CI: 1.5-1.9%, P < 0.001). The proportion of ungradable images was higher in the group ≥70 year (14.4%, 95% CI:13.1-15.7% vs. 6.1%, 95% CI: 5.7-6.5%, P < 0.001), particularly in phakic eyes, although 80% of patients had interpretable images for both eyes. Pupil dilation significantly improved image quality in this group. Screening also allowed detecting other ocular disorders, including age-related macular degeneration and glaucoma, which were more common in the group ≥ 70 years (2.1%, 95% CI: 1.5-2.6% vs. 0.6%, 95% CI: 0.4-0.7% P < 0.001). Teleophthalmology-based DR screening appeared feasible and clinically relevant in patients aged ≥70 years, allowing identifying patients requiring ophthalmologic evaluation, while also detecting other age-related ocular diseases. Pupil dilation is recommended to optimize image quality in this population.

#2

Interventions for submacular haemorrhage: A systematic review and network meta-analysis of controversies-On behalf of the Spanish Vitreo-Retinal Society (SERV).

Acta ophthalmologica2026 Mar

This systematic review aims to evaluate and synthesize the existing literature on the interventions used for submacular haemorrhage (SMH), highlighting the controversies and differences in clinical practice. A systematic review was conducted following the PRISMA guidelines. A comprehensive search was performed across multiple databases, including MEDLINE, EMBASE and Cochrane Library, to identify studies on SMH treatment. Inclusion criteria encompassed randomized controlled trials, cohort studies and case series that focused on different therapeutic interventions. Data on functional outcomes, efficacy and safety of the interventions were extracted and analysed. The review included 150 studies, of which 38 were included in the network meta-analysis. The analysis of best corrected visual acuity (BCVA) Included 26 studies, 20 interventions and 2125 eyes. Heterogeneity was moderate (I2 = 28.9%). Non-vitrectomy therapies showed better BCVA outcomes and fewer complications (e.g. retinal detachment, vitreous haemorrhage), while vitrectomy-based treatments achieved better anatomical results. According to P-score ranking, "Observation" had the highest probability of being most effective for BCVA (P-score = 0.8051), followed by anti-VEGF monotherapy and non-vitrectomy combinations. However, this result should be interpreted cautiously, as the "Observation" group was based on only two studies (26 eyes) with clinical heterogeneity. No publication bias was detected (Egger's test p = 0.582). There is no consensus on a standard evidence-based treatment for SMH. Minimally invasive strategies are promising, but factors such as timing, lesion size and anti-VEGF use remain critical. Further large-scale randomised trials are needed to define optimal management.

#3

The role of complement factor I rare genetic variants in age related macular degeneration in Finland.

Human molecular genetics2025 Feb 01

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the developed world. The alternative pathway (AP) of complement has been linked to the pathogenesis of AMD. In particular, rare variants (RVs) in the complement factor I (CFI) gene encoding the Factor I (FI) protein confer increased AMD risk. The prevalence of CFI RVs are well characterised in European AMD, however little is known about other populations. The Finnish population underwent genetic restriction events which have skewed allele frequencies in unexpected ways. A series of novel or enriched CFI RVs were identified in individuals with dry AMD from the Finnish Biobank Cooperative (FINBB), but the relationship between these genotypes and contribution to disease was unclear. Understanding how RVs impact the ability of FI to regulate the complement system is important to inform mechanistic understanding for how different genotypes contribute to disease development. To explore this a series of in vitro assays were used to functionally characterise the protein products of 3 CFI RVs enriched in FINBB dry AMD, where no prior data were available. The G547R variant resulted in almost complete loss of both classical pathway and AP regulatory potential. The c.982 g>a variant encoding G328R FI perturbed an exon splice enhancer site which resulted in exon skipping and a premature stop codon in vitro and low levels of FI in vivo. Despite detailed analysis no defect in levels or function was demonstrated in T107A. Functional characterization of all Finnish CFI RVs in the cohort allowed us to demonstrate that in Finnish dry AMD, collectively the type 1 CFI RVs (associated with FI haploinsufficiency) were significantly enriched with odds ratio (ORs) of 72.6 (95% confidence interval; CI 16.92 to 382.1). Meanwhile, type 2 CFI RVs (associated with FI dysfunction) collectively conferred a significant OR of 4.97 (95% CI 1.522 to 15.74), and non-impaired or normal CFI RV collectively conferred an of OR 3.19 (95% CI 2.410 to 4.191) although this was driven primarily by G261D. Overall, this study for the first time determined the ORs and functional effect for all CFI RVs within a Geographic Atrophy (GA) cohort, enabling calculations of combined risk scores that underline the risk conferred by type 1 and 2 CFI RVs in GA/AMD.

#4

Exploring Concomitant Ophthalmic Comorbidities in Portuguese Patients with Inherited Retinal Diseases: A Comprehensive Clinical Study.

Genes2025 Jun 26

Background/Objectives: Inherited retinal diseases (IRDs) are a heterogeneous group of rare eye disorders characterized by progressive photoreceptor degeneration, leading to severe visual impairment or even blindness. This study aims to investigate the prevalence, types, and clinical significance of ophthalmic comorbidities in Portuguese patients with IRDs. Methods: This nationwide Portuguese population-based retrospective study was based on the IRD-PT registry (retina.com.pt). Statistical analysis was conducted using Microsoft® Excel® for Microsoft 365 and IBM SPSS Statistics version 29.0.2.0. Informed consent was obtained from all participants. Results: A total of 1531 patients (1254 families) from six centers were enrolled. The cohort consisted of 51% males, with a mean age of 45.8 ± 19.3 years and a mean age at diagnosis of 39.4 ± 19.5 years. Overall, ocular comorbidities were reported in 644 patients (42.1%). In 176 individuals (11.5%), multiple concurrent comorbidities were found. Cataract was the most common comorbidity (21.3%), followed by amblyopia (6.3%) and high myopia (5.9%). Statistically significant associations with ocular comorbidities were observed in isolated progressive IRDs. Specifically, AR RP was associated with cataract (p < 0.001), and gene analysis revealed several significant associations. CRB1 was statistically linked to epiretinal membrane (ERM) (p = 0.003), EYS with cataract (p = 0.001), PROM1 with choroidal neovascularization (CNV) (p = 0.0026), and USH2A with macular hole (p = 0.01). Patients with the RPE65 mutation in Leber congenital amaurosis were associated with ERM (p = 0.019). There was also a significant association between X-linked RP and high myopia (p < 0.001) and CNV in Best disease (p < 0.001); in syndromic IRDs, cataract, cystoid macular edema, and ERM were observed in Usher syndrome, p = 0.002, p = 0.002, and p = 0.005, respectively, and the MYO7A gene was linked to cataract (p = 0.041) and strabismus (p = 0.013); pseudoxanthoma elasticum was significantly associated with CNV (p = 0.002); and foveal hypoplasia was associated with anterior segment dysgenesis (p < 0.001). Conclusions: This study enhances the current understanding of ocular comorbidities in IRDs in Portuguese patients. Common findings were cataract, refractive error, and CME. Stationary IRDs and pattern dystrophies showed fewer concomitant comorbidities, supporting their classification as non-progressive or benign conditions. The significance of registries like IRD-PT cannot be overstated, particularly in the context of rare diseases. These databases serve multiple crucial functions in enabling detailed documentation of disease characteristics and long-term monitoring of disease progression.

#5

Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.

Trials2024 Apr 22

Macular edema (ME) results from hyperpermeability of retinal vessels, leading to chronic extravasation of plasma components into the retina and hence potentially severe visual acuity loss. Current standard of care consists in using intravitreal injections (IVI), which results in a significant medical and economic burden. During diabetic retinopathy (DR) or retinal vein occlusion (RVO), it has recently been shown that focal vascular anomalies (capillary macro-aneurysms, also termed TelCaps) for telangiectatic capillaries may play a central role in the onset, early recurrence, and/or persistence of ME. Since targeted photocoagulation of TelCaps may improve vision, identification, and photocoagulation of TelCaps, it may represent a way to improve management of ME. The Targeted Laser in (Diabetic) Macular Edema (TalaDME) study aims to evaluate whether ICG-guided targeted laser (IGTL), in association with standard of care by IVI, allows reducing the number of injections during the first year of treatment compared with IVI only, while remaining non-inferior for visual acuity. TalaDME is a French, multicentric, two-arms, randomized, sham laser-controlled, double-masked trial evaluating the effect of photocoagulation of TelCaps combined to IVI in patients with ME associated with TelCaps. Patients with vision loss related to center involved ME secondary to RVO or DR and presenting TelCaps are eligible. Two hundred and seventy eyes of 270 patients are randomized in a 1:1 ratio to standard care, i.e., IVI of anti-VEGF solely (control group) or combined with IGTL therapy (experimental group). Stratification is done on the cause of ME (i.e., RVO versus diabetes). Anti-VEGF IVI are administered to both groups monthly for 3 months (loading dose) and then with a pro re nata regimen with a monthly follow-up for 12 months. The primary endpoint will be the number of IVI and the change in visual acuity from baseline to 12 months. Secondary endpoints will be the changes in central macular thickness, impact on quality of life, cost of treatment, and incremental cost-utility ratio in each groups. Rare but severe AE linked to the use of IVI and laser, and previously described, are expected. In the sham group, rescue laser photocoagulation may be administered by the unmasked investigator if deemed necessary at month 3. The best management of ME associated with TelCaps is debated, and there have been no randomized study designed to answer this question. Given the fact that TelCaps may affect 30 to 60% of patients with chronic ME due to DR or RVO, a large number of patients could benefit from a specific management of TelCaps. TalaDME aims to establish the clinical and medico-economic benefits of additional targeted laser. The results of TalaDME may raise new recommendations for managing ME and impact healthcare costs. EudraCT: 2018-A00800-55/ NCT03751501. Registration date: Nov. 23, 2018.

Publicações recentes

Ver todas no PubMed

📚 EuropePMCmostrando 22

2026

Telemedicine-based diabetic retinopathy screening in patients over 70 Years: a French cohort study within the OPHDIAT network.

Diabetes &amp; metabolism
2026

Interventions for submacular haemorrhage: A systematic review and network meta-analysis of controversies-On behalf of the Spanish Vitreo-Retinal Society (SERV).

Acta ophthalmologica
2025

Exploring Concomitant Ophthalmic Comorbidities in Portuguese Patients with Inherited Retinal Diseases: A Comprehensive Clinical Study.

Genes
2025

The role of complement factor I rare genetic variants in age related macular degeneration in Finland.

Human molecular genetics
2024

Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.

Trials
2023

Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration.

The Cochrane database of systematic reviews
2023

Static Perimetry in the Rate of Progression in USH2A-related Retinal Degeneration (RUSH2A) Study: Assessment Through 2 Years.

American journal of ophthalmology
2023

Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis/retinal vascular occlusion adverse events.

Science translational medicine
2023

Effective smMIPs-Based Sequencing of Maculopathy-Associated Genes in Stargardt Disease Cases and Allied Maculopathies from the UK.

Genes
2022

Five-Year Cumulative Incidence and Progression of Myopic Maculopathy in a German Population.

Ophthalmology
2021

A systematic review of cases of West African crystalline maculopathy.

International journal of clinical practice
2021

[Intraocular inflammation with brolucizumab use : Patient management-diagnosis-therapy].

Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft
2021

Retinal Phenotype of Patients With Isolated Retinal Degeneration Due to CLN3 Pathogenic Variants in a French Retinitis Pigmentosa Cohort.

JAMA ophthalmology
2021

Current Clinical Applications of In Vivo Gene Therapy with AAVs.

Molecular therapy : the journal of the American Society of Gene Therapy
2020

Genotype-Phenotype Correlations in a Spanish Cohort of 506 Families With Biallelic ABCA4 Pathogenic Variants.

American journal of ophthalmology
2020

European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management.

Journal of clinical immunology
2019

Chronic and recurrent non-infectious paediatric-onset uveitis: a French cohort.

RMD open
2019

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration.

The Cochrane database of systematic reviews
2019

Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK.

Advances in therapy
2018

Dietary, environmental, and genetic risk factors of Extensive Macular Atrophy with Pseudodrusen, a severe bilateral macular atrophy of middle-aged patients.

Scientific reports
2018

Geographic distribution of rare variants associated with age-related macular degeneration.

Molecular vision
2015

Biallelic mutations in the autophagy regulator DRAM2 cause retinal dystrophy with early macular involvement.

American journal of human genetics

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para NÃO RARA NA EUROPA: Degenerescência macular relacionada com a idade.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para NÃO RARA NA EUROPA: Degenerescência macular relacionada com a idade

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Telemedicine-based diabetic retinopathy screening in patients over 70 Years: a French cohort study within the OPHDIAT network.
    Diabetes &amp; metabolism· 2026· PMID 41547437mais citado
  2. Interventions for submacular haemorrhage: A systematic review and network meta-analysis of controversies-On behalf of the Spanish Vitreo-Retinal Society (SERV).
    Acta ophthalmologica· 2026· PMID 40772916mais citado
  3. The role of complement factor I rare genetic variants in age related macular degeneration in Finland.
    Human molecular genetics· 2025· PMID 39584280mais citado
  4. Exploring Concomitant Ophthalmic Comorbidities in Portuguese Patients with Inherited Retinal Diseases: A Comprehensive Clinical Study.
    Genes· 2025· PMID 40725401mais citado
  5. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
    Trials· 2024· PMID 38649937mais citado
  6. Gene therapy of rare diseases as a milestone in medicine - overview of the field and report on initial experiences in Slovenia.
    Orphanet J Rare Dis· 2025· PMID 40474241recente
  7. Rehabilitation for spinal muscular atrophy patients in China: a national cross-sectional study.
    Orphanet J Rare Dis· 2024· PMID 39060931recente
  8. Challenges for gene therapy in the financial sustainability of health systems: a scoping review.
    Orphanet J Rare Dis· 2024· PMID 38915120recente
  9. Myocardial analysis from routine 4D cardiac-CT to predict reverse remodeling and clinical outcomes after transcatheter aortic valve implantation.
    Eur J Radiol· 2024· PMID 38490128recente
  10. The burden of hospital admissions for skeletal dysplasias in Sri Lanka: a population-based study.
    Orphanet J Rare Dis· 2023· PMID 37684696recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:279(Orphanet)
  2. MONDO:0005150(MONDO)
  3. Variantes catalogadas(ClinVar)
  4. Busca completa no PubMed(PubMed)
  5. Artigo Wikipedia(Wikipedia)
  6. Q27429789(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

NÃO RARA NA EUROPA: Degenerescência macular relacionada com a idade
Compêndio · Raras BR

NÃO RARA NA EUROPA: Degenerescência macular relacionada com a idade

ORPHA:279 · MONDO:0005150
MedGen
UMLS
C0024437
Repurposing
3 candidatos
anecortave-acetateangiogenesis inhibitor
luteinantioxidant
verteporfinphotosensitizing agent
Wikidata
Wikipedia
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades